肝动脉栓塞联合三氧化二砷治疗原发性肝癌91例观察

Efficacy of transcatheter arterial chemoembolization combined with arsenic trioxide in the treatment of primary liver cancer for gl cases

目的观察肝动脉栓塞（TACE）联合三氧化二砷（AS2O3）治疗原发性肝癌的近期疗效。方法91例中晚期原发性肝癌患者采用常规化疗药物经皮肝动脉栓塞治疗，每4周重复，同时给予三氧化二砷注射液10-15mg静脉滴注，每日1次，连用14d，每4周重复为1个疗程，2—3个疗程后观察疗效。结果近期疗效：完全缓解3例，部分缓解42例，稳定35例，进展11例，总有效率61．7％。生活质量：改善61例，稳定24例。不良反应轻。结论肝动脉化疗栓塞联合静脉注射三氧化二砷治疗中晚期原发性肝癌近期疗效较好，毒副作用小。

Objective To investigate the short term efficacy of transcatheter arterial chemoembolization（ TACE） combined with arsenic trioxide（ AS203 ） in the treatment of primary liver cancer. Methods 91 patients with advanced primary liver cancer underwent routine hepatic arterial chemoembolization, repeated every 4 weeks for 2 to 3 cycles. In each cycle of chemoembolization,AS203 ,was injected intravenously once a day for 2 weeks at a dose of 10 - 15mg. Results All patients completed 2 - 3 cycles treatment and followed for more than one year. Total response rate was 61.7% and clinical benefit rate was 42 cases of partial response（PR） ,35 cases of no changes（NC） and 11 cases of progressive disease（PD）. Quality of life improved in 61 cases and stabilized in 24 cases. Toxicities was mild and tolerable. Conclusion TACE combined with arsenic trioxide in the treatment of primary liver cancer is efficient with a mild toxicities.